AMW and SAJA Pharmaceuticals sign license and supply agreement for commercialization of AMW’s goserelin implant

Warngau and Jeddah, Kingdom of Saudi Arabia, January 9, 2023

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, and SAJA Pharmaceuticals, a leading regional drug manufacturer based in Jeddah, Saudi Arabia, with a presence in the MENA (North Africa and Middle East) states, announced today that they have entered into an exclusive licensing and supply agreement. The agreement covers the commercialization of AMW’s goserelin implant in the Kingdom of Saudi Arabia.

“We are proud of being able to partner with SAJA, who stands for high-quality pharmaceutical products in the Kingdom of Saudi Arabia and beyond,” commented Dr. Konstantin Petropoulos, CEO of AMW. “This collaboration contributes to our strategy of providing value-added and cost-effective treatments to patients in need, specifically in the MENA region.”

“We are extremely happy to have AMW as a partner, being able to provide patients in the Kingdom of Saudi Arabia with high-quality, advanced products,” added Dr. Mohammed Khalil, CEO of SAJA. “We look forward to enrich the patient’s journey and maximize treatment options by offering AMW’s goserelin implant in our home market.”

AMW develops and produces innovative, biodegradable sustained-release drug delivery systems, such as the GnRH analogue implants goserelin and leuprorelin. For global commercialization, the products are licensed to international and regional partners. To date, goserelin has been licensed to leading global and local pharmaceutical enterprises in more than 50 countries. In Germany, AMW’s products are distributed by the Company’s wholly owned subsidiary Endomedica GmbH.

About AMW:

AMW GmbH is a specialty pharmaceutical company focused on biodegradable sustained-release drug delivery systems, providing patients and partners access to value-added medicines and cost-effective therapies. Based on its technology platform, the Company builds on a growing own and partnered development pipeline. AMW has two approved products, goserelin and leuprorelin implants, which are distributed worldwide through both local and global pharma partners. In Germany, leuprorelin is marketed as Leugon^® by AMW’s wholly owned subsidiary Endomedica GmbH. To support pharma and biotech partners in the development and manufacturing of their products and life-cycle solutions, AMW uses its leading-edge formulation development expertise.

AMW is based in Warngau near Munich, Germany.

About SAJA Pharmaceuticals:

SAJA Pharmaceuticals is a joint venture between the premier Saudi healthcare company Tamer Industries and two of the leading Japanese pharmaceutical companies which are Daiichi Sankyo Company Ltd and Astellas Pharma Inc.

About Goserelin:

Goserelin implants contain the active ingredient goserelin and belong to the class of GnRH agonists (analogues of gonadotropin releasing hormone) which interfere with the regulation of sex hormone balance. As a consequence, testosterone levels are lowered in men and estradiol levels are lowered in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormone-dependent tumors such as prostate cancer or breast cancer. In addition, goserelin implant is used to treat certain benign gynecological disorders. Goserelin is administered in the form of a biodegradable implant which releases the active ingredient over a period of either one or three months.

For further information please contact:

AMW GmbH

Dr. Konstantin Petropoulos

Phone: +49 8024 470999-0

E-mail: news@a-m-w.eu

SAJA pharmaceuticals company

Dr. Mohammed Khalil

Phone: +966 12 6066 667

E-mail : info@sajapharma.com